Diclegis, combining vitamin B6 and doxylamine succinate, carries regulatory approval from the FDA and European Medicines Agency as safe and effective for moderate-to-severe pregnancy nausea. This clinical endorsement reflects decades of international use and established safety profiles in pregnancy populations. However, NHS patients should be aware that access to this medication depends significantly on their geographic location.
Pregnant women may face three distinct scenarios depending on their NHS trust: full funding coverage, restricted access requiring additional justification, or no coverage requiring private purchase. This means clinical need alone does not guarantee access—postcode and trust formulary policies play decisive roles. Women experiencing significant nausea should discuss diclegis with their healthcare provider and understand their local trust’s policies.
These disparities highlight the importance of advocating for standardised, evidence-based formulary decisions across NHS trusts to ensure all pregnant women can access approved treatments based on clinical need rather than geography or financial resources.
Read the full article on GMJ Newsroom.
Was this article helpful?
